FIELD: medicine; pharmacology.
SUBSTANCE: invention can be used to correct metabolic disorders, in particular, arising in diabetes mellitus, obesity and metabolic syndrome. What is presented is the use of a clathrate complex of 3-(2-phenylethyl)-2-thioxo-1,3 thiazolidin-4-one with β-cyclodextrin for the correction of metabolic disorders.
EFFECT: providing effective correction of metabolic disorders, including hyperglycemia and dyslipidemia.
5 cl, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF RHODANINE DERIVATIVE 3-(2-PHENYLETHYL)-2-THIOXO-1,3 THIAZOLIDIN-4-ONE FOR NORMALIZATION OF METABOLISM, INCREASE OF NON-SPECIFIC RESISTANCE, GROWTH AND DEVELOPMENT OF ANIMALS | 2019 |
|
RU2768456C2 |
| USE OF CLATHRATE COMPLEX OF 20-HYDROXYECDYSONE WITH ARABINOGALACTAN FOR NORMALIZATION OF METABOLISM, INCREASE IN NON-SPECIFIC RESISTANCE, GROWTH AND DEVELOPMENT OF ANIMALS | 2019 |
|
RU2776671C2 |
| METHOD FOR COMBINED USE OF INTRANASALLY ADMINISTERED INSULIN AND ORALLY ADMINISTERED METFORMIN FOR RECOVERY OF METABOLIC AND HORMONAL PARAMETERS IN TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME | 2023 |
|
RU2824275C1 |
| METHOD FOR INSULIN RESISTANCE CORRECTION IN METABOLIC SYNDROME | 2009 |
|
RU2402326C1 |
| METHOD FOR TREATMENT OF TYPE 2 DIABETES MELLITUS | 2005 |
|
RU2304976C1 |
| METHOD OF TREATING ABDOMINAL OBESITY IN CASE OF METABOLIC SYNDROME | 2013 |
|
RU2548709C1 |
| MATERIALS AND METHODS FOR METABOLISM MODULATION | 2005 |
|
RU2387445C2 |
| SOLID-PHASE COMPOSITION FOR CORRECTION OF METABOLIC DISORDERS IN TYPE 2 DIABETES MELLITUS | 2020 |
|
RU2747985C1 |
| METHOD OF SYNTHESIS OF GAMMA-L-GLUTAMYLHISTAMINE, USE OF GAMMA-L-GLUTAMYLHISTAMINE, PHARMACEUTICAL COMPOSITION | 1997 |
|
RU2141968C1 |
| AGENT FOR METABOLIC SYNDROME CORRECTION | 2011 |
|
RU2458935C1 |
